Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25,562 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Critical Appraisal of Amyloid Lowering Agents in AD.
Decourt B, Boumelhem F, Pope ED 3rd, Shi J, Mari Z, Sabbagh MN. Decourt B, et al. Among authors: shi j. Curr Neurol Neurosci Rep. 2021 Jun 10;21(8):39. doi: 10.1007/s11910-021-01125-y. Curr Neurol Neurosci Rep. 2021. PMID: 34110536 Free PMC article. Review.
Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
Curtis C, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Holmes C, Escovar YM, Vera CX, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Grachev ID, Farrar G, Smith AP, Buckley CJ, McLain R, Salloway S. Curtis C, et al. Among authors: shi j. JAMA Neurol. 2015 Mar;72(3):287-94. doi: 10.1001/jamaneurol.2014.4144. JAMA Neurol. 2015. PMID: 25622185 Free article. Clinical Trial.
Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease.
Salloway S, Gamez JE, Singh U, Sadowsky CH, Villena T, Sabbagh MN, Beach TG, Duara R, Fleisher AS, Frey KA, Walker Z, Hunjan A, Escovar YM, Agronin ME, Ross J, Bozoki A, Akinola M, Shi J, Vandenberghe R, Ikonomovic MD, Sherwin PF, Farrar G, Smith APL, Buckley CJ, Thal DR, Zanette M, Curtis C. Salloway S, et al. Among authors: shi j. Alzheimers Dement (Amst). 2017 Jul 1;9:25-34. doi: 10.1016/j.dadm.2017.06.001. eCollection 2017. Alzheimers Dement (Amst). 2017. PMID: 28795133 Free PMC article.
Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
Wolk DA, Sadowsky C, Safirstein B, Rinne JO, Duara R, Perry R, Agronin M, Gamez J, Shi J, Ivanoiu A, Minthon L, Walker Z, Hasselbalch S, Holmes C, Sabbagh M, Albert M, Fleisher A, Loughlin P, Triau E, Frey K, Høgh P, Bozoki A, Bullock R, Salmon E, Farrar G, Buckley CJ, Zanette M, Sherwin PF, Cherubini A, Inglis F. Wolk DA, et al. Among authors: shi j. JAMA Neurol. 2018 Sep 1;75(9):1114-1123. doi: 10.1001/jamaneurol.2018.0894. JAMA Neurol. 2018. PMID: 29799984 Free PMC article.
Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease.
Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, Jacobson SA, Belden CM, Caselli RJ, Woodruff BK, Rapscak SZ, Ahern GL, Shi J, Caviness JN, Driver-Dunckley E, Mehta SH, Shprecher DR, Spann BM, Tariot P, Davis KJ, Long KE, Nicholson LR, Intorcia A, Glass MJ, Walker JE, Callan M, Curry J, Cutler B, Oliver J, Arce R, Walker DG, Lue LF, Serrano GE, Sue LI, Chen K, Reiman EM. Malek-Ahmadi M, et al. Among authors: shi j. PLoS One. 2019 Jun 25;14(6):e0217566. doi: 10.1371/journal.pone.0217566. eCollection 2019. PLoS One. 2019. PMID: 31237877 Free PMC article.
25,562 results
You have reached the last available page of results. Please see the User Guide for more information.